StreetAlpha.app
Home › Stocks › OVID

Ovid Therapeutics Inc. (OVID)

Healthcare
$2.22
▼ −7.50%
LAST CLOSE · NOV 17

Ovid develops small molecule medicines for brain disorders such as epilepsy, seizure disorders and psychosis. It last closed at $2.22 on Nov 17, down 7.50% on the day. The average 12-month price target from 3 analysts is $5.67 (+155.3% from the last close), with a high of $7.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $191K, the largest $191K.

AI Auto Pilots
Is OVID in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5M
−78.0% vs a year ago
Net income
−$43.1M
−2967.2% margin
Operating margin
−4693.7%
−$68.2M operating income
Valuation
Market cap
$419.0M
188.7M shares
P/E
–
Price to sales
288.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$13.8M
At Sep 30
Shareholder equity
$198.7M
Shares outstanding
188.7M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $208.4M$208.4MFY2021FY2022: $1.5M$1.5MFY2022FY2023: $392K$392KFY2023FY2024: $566K$566KFY2024FY2025: $7.3M$7.3MFY2025

From OVID's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on OVID in the past 90 days
Average 12-month target
$5.67
▲ 155.3% upside

Based on 3 analysts who set a price target on OVID in the past 90 days. The average target is $5.67, with a high of $7.00 and a low of $5.00, compared with the last close of $2.22.

Low $5.00Avg $5.67High $7.00
Blue marker: last close $2.22
Highest target$7.00
Average target$5.67
Lowest target$5.00
Latest rating changes
Wolfe ResearchInitiated
Oct 15Buy$5
GuggenheimInitiated
Oct 5Buy$7
HC Wainwright & Co.Maintained
Sep 11Buy$5
OppenheimerMaintained
Aug 3Buy$9
DateFirmActionRatingPrice target
Oct 15Wolfe ResearchInitiatedBuy$5
Oct 5GuggenheimInitiatedBuy$7
Sep 11HC Wainwright & Co.MaintainedBuy$5
Aug 3OppenheimerMaintainedBuy$9
Loading…

Technical Analysis

OVID · as of the Nov 17 close · updated after every close
Turning down

The stock is 13% below its 20 day and 12% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Jul 31) at $2.20, and the nearest resistance the Pivot at $2.26.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 10.2%/day
Key levels
$3.1152 week high+40.1%
$2.55100 day average+14.9%
$2.5020 day average+12.6%
$2.4950 day average+12.2%
$2.49Swing high (Oct 12)+12.2%
$2.42200 day average+9.0%
$2.36Pivot R1+6.3%
$2.26Pivot+1.8%
$2.22Last close
$2.20Swing low (Jul 31)−0.9%
$2.12Pivot S1−4.5%
$1.2152 week low−45.5%
Indicators
RSI (14)40.15Middle of its rangeNeutral
MACD0.02Below its signal lineBearish
Stochastic24.2Middle of its rangeNeutral
ADX (14)22.4Weak trend
Williams %R-93.5Oversold below −80, overbought above −20Oversold
CCI (20)-102.6Oversold below −100, overbought above 100Oversold
Rate of change−7.5%Change over 10 sessionsBearish
ATR (14)$0.23Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OVID

What happened before

See how OVID did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OVID usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OVID has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OVID in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$191K
Largest print
$191K
Loading…

OVID Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲67 buying vs 44 selling
  • ▲Held by funds +0.7 pts
  • ▼Funds holding -2
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding129131−1.5%
In funds' top 1000–
Held by funds78.6%77.9%+0.7 pts
New / increased13 / 5446 / 33−15.2%
Reduced / sold out30 / 1427 / 18−2.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OVID institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OVID is in one of them and how their past OVID trades turned out.

OVID in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OVID in an article yet. Here's the latest on the wider market.

About Ovid Therapeutics

Ovid is a biopharmaceutical company that develops small molecule medicines for disorders of the brain and nervous system. Its work centers on epilepsy, seizure disorders and psychosis, with medicines designed to calm overactive nerve cells. Its programs are in clinical trials, and the company aims to serve patients with seizure and psychiatric conditions that have few treatment options. Ovid is based in New York.

Headquarters
New York, NY